EvolusEOLS
Recorded

Evolus 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration38 minParticipants10

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

I would now like to turn the conference over to your host, Nareg Sagherian, Vice President and Head of Global Investor Relations and Corporate Communications. Please go ahead. Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' third quarter financial results.

Nareg SagherianVP and Head of Global Investor Relations and Corporate Communications

Our third quarter press release is now available on the Investor Relations section of our website at evolus.com. Joining me on today's call are David Moatazedi, President and Chief Executive Officer, Rui Avelar, Chief Medical Officer and Head of R&D, and Tatjana Mitchell, Chief Financial Officer. Today's call will include forward-looking statements. Actual results may differ materially due to risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to, and not as a substitute for, our GAAP results. A reconciliation of GAAP to non-GAAP measures is included in today's earnings release.

Nareg SagherianVP and Head of Global Investor Relations and Corporate Communications

As a reminder, our earnings release and SEC filings are available on the SEC's website and on our Investor Relations website. Following the conclusion of today's call, a replay will be available on our website at investors.evolus.com. With that, I'll turn the call over to our CEO, David Moatazedi.

David MoatazediPresident and CEO

Thank you, Nareg, and good afternoon, everyone. I'm pleased to report our fourth consecutive quarter of positive adjusted EBITDA and continued above-market growth while continuing to expand our portfolio with differentiated assets. These results reflect our deliberate strategy to build on the strength of our established brands while creating additional opportunities for long-term growth. Evolus is now a more diversified global performance beauty company with a growing international commercial portfolio, an expanding pipeline, and improving financial performance. At the beginning of the year, we outlined three priorities to guide our progress: commercial execution, financial discipline, and pipeline expansion. Let me update you on each priority. On commercial execution, global toxin revenue grew approximately 11% both in the third quarter and year to date, while our newly launched HA business grew nearly 40% in the quarter and more than 50% year to date.

David MoatazediPresident and CEO

On financial discipline, we delivered our fourth consecutive quarter of positive adjusted EBITDA while continuing to invest in our commercial priorities and portfolio development. Importantly, through the first nine months, revenue grew 14% while we maintained nearly flat non-GAAP operating expenses, demonstrating the outstanding leverage of our portfolio of products. On pipeline expansion, we have added skin quality as a third pillar within our U.S. facial injectable pipeline through our partnership with IBSA for Profhilo. We also recently announced an early-stage option agreement in procedure-based injectable hair growth, which adds a longer-term opportunity in a complementary aesthetic category. Turning to the quarter, we are operating in a healthy global aesthetics market, with consumers continuing to prioritize beauty and their appearance despite softer consumer confidence.

David MoatazediPresident and CEO

We believe the category is strengthening in the U.S., supported in part by broader adoption of GLP-1 therapies, which is bringing new patients into aesthetic practices and creating additional treatment needs following weight loss. These strong tailwinds reinforce our confidence in the opportunity ahead. We delivered $78 million in revenue in the third quarter, up 13% year-on-year. Through the first nine months, adjusted EBITDA reached positive $6.4 million compared with a loss of $16.5 million a year ago, an improvement of approximately $23 million. These results demonstrate our progress in translating commercial growth into improved financial performance while continuing to make investments in the business. Jeuveau remains the foundation of our commercial platform. Its continued growth reflects our focus on customer experience, clinical education, and consumer loyalty, which supports share gains and strengthens our relationships with aesthetic practices.

David MoatazediPresident and CEO

As we expand the portfolio, our established relationships and infrastructure have provided an opportunity to introduce complementary brands and become a more meaningful partner for our clinics. We are seeing that opportunity develop with our Evolysse portfolio. More than 4,500 customers have now purchased Evolysse, providing a foundation for continued adoption and increased utilization within practices. Our focus remains on building confidence with the portfolio through education, service, and experience of the product. As we did with Jeuveau, we are converting initial adoption into sustained use, increasing the overall value of our partnership within aesthetic practices. Our growth continues to be supported by an expanding customer base and sustained consumer engagement. During the quarter, we added over 500 purchasing accounts, bringing our cumulative customer base to more than 19,000.

David MoatazediPresident and CEO

Evolus Rewards membership grew 23% year-over-year to more than 1.6 million consumers, with approximately 70% of existing patients returning for repeat treatment. Together, these trends demonstrate our ability to attract new patients practices and build the loyalty that supports sustained growth as we continue to expand the portfolio. Internationally, we are extending the same portfolio approach. Following the successful launch of Estyme in Europe, we expanded our relationship with Symatese in August to include Canada, Australia, and New Zealand. We now hold exclusive rights to the Evolysse portfolio in every market where we currently offer Jeuveau and Nuceiva. Strategically, this alignment gives us the opportunity to build a consistent multi-product offering across our global business, with a broader set of brands supported by our existing commercial infrastructure. Our financial performance this year demonstrates the operating leverage that makes this portfolio strategy compelling.

David MoatazediPresident and CEO

We are growing revenue and improving profitability through a platform designed to support multiple injectable brands. Additional products can address more treatment needs within the same practices, allowing us to build on existing customer relationships, digital capabilities, and commercial infrastructure. This platform provides a commercial foundation for the next stage of our U.S. portfolio. As we look ahead, we plan to introduce three additional products over the next four years. This expansion builds on Jeuveau and the first two formulations of Evolus. Within Evolus, we expect Sculpt to be our next launch, followed by Lips. Beyond these launches, our partnership with IBSA supports the U.S. development and commercialization of Profhilo, the market-leading skin quality injectable in Europe. We are also building opportunities beyond that launch horizon. Our early-stage option agreement in procedure-based injectable hair growth adds a longer-term opportunity that is complementary to the aesthetic practices we serve.

David MoatazediPresident and CEO

This gives us a portfolio spanning established commercial products advancing towards anticipated launches, and earlier-stage opportunities that can broaden our growth over time. With that, I'd like to turn the call over to Rui to talk you through the portfolio in more detail, beginning with our commercial products. He will then update you on the products advancing through development and regulatory review, followed by our longer-term opportunities.

Rui AvelarChief Medical Officer and Head of R&D

Thank you, David. In Europe, we launched our full line of hyaluronic acid injectables under the brand name Estyme, known as Evolus here in the U.S. Our confidence in this HA line continues to build, and the feedback we're receiving remains consistent with our initial assessment. Injectors describe the gels as highly efficient in terms of correction achieved with a given amount of product, having good tissue integration, providing natural-looking results, and very dynamic, particularly in areas of tissue movement. Another consistent theme is predictability, being able to correct to the desired aesthetic outcome without having to adjust technique to account for gel swelling over time. Regarding late-stage development programs, Evolysse Sculpt remains under FDA review, and we continue to anticipate approval in the fourth quarter of 2026. The Evolysse Lips program is nearing the final stages, and we anticipate submitting the PMA to the FDA before the year end.

Rui AvelarChief Medical Officer and Head of R&D

As we expand the pipeline, we continue to build on our performance beauty strategy and have consistently expressed interest in skin quality, hair growth, and biostimulators as opportunities to broaden the portfolio. On our last call, we introduced Profhilo, establishing skin quality as the third category within our facial injectable portfolio. Since the announcement, we've received substantial inbound interest, particularly from U.S. injectors aware of the product in Europe, where it commands a market-leading share position. Profhilo is unlike any other HA on the market and highly complementary to the Evolus injectable line. Evolus is manufactured using a traditional cross-linker and is engineered to soften features, support tissue, and create projection. Profhilo is designed to address skin quality and hydrate the skin from within, which requires a different set of performance characteristics. IBSA, the parent company, developed a unique proprietary manufacturing process to achieve this.

Rui AvelarChief Medical Officer and Head of R&D

Using a thermal process, high molecular weight HA bonds are weakened. Then, during cooling, low molecular weight HA is intertwined, forming new hydrogen bonds, creating a novel stabilized hybrid complex, ideally suited to address skin quality. The FDA development program is already underway, and as a reminder, Evolus will own the PMA at the end of this process. Turning to hair growth. We recently announced an agreement that gives Evolus the option to acquire a hair growth asset. We've had clear criteria that would make an opportunity in this category attractive to us. The therapeutic needs to be locally delivered. Oral therapies become systemic, which can increase the potential for adverse events, including hair growth in unwanted parts of the body. Women are especially sensitive to this. A well-characterized therapeutic agent. Our focus is on compounds that have shown efficacy in hair growth, helping to de-risk the program.

Rui AvelarChief Medical Officer and Head of R&D

It needs to be a procedure. Our customers are skilled injectors. They want to perform procedures to deliver therapeutics, making an in-office treatment approach a natural fit with their practices. Finally, we're targeting a quarterly treatment interval. The current formulation under development is aiming for a three-month interval, complementing the cadence that practices like to see their patients. The hair growth program is a longer-term blue-sky pipeline opportunity, and the risk is further mitigated by the design of the arrangement. The option to acquire the company will be based on actual human data, which should be more predictive of probability of success than animal data. We will be able to see and assess the results before having to commit to the acquisition and the full development program. In summary, we continue to anticipate Sculpt launch in 2027, a Lips submission this year, then followed with launch in early 2028.

Rui AvelarChief Medical Officer and Head of R&D

Profhilo represents a midterm opportunity, with approval anticipated around 2030. Together, these programs support our plans for three product launches over the next four years. Hair represents a longer-term opportunity and has the potential to become an Evolus fully owned asset, where we would own it from manufacturing to final sale of the product. On biostimulators, we remain active in discussions with potential assets while maintaining discipline around the terms and the structure of any agreement we pursue. With that, I'll turn the call over to Tatjana.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day